Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A novel nanoparticle containing neuritin peptide with grp170 induces a CTL response to inhibit tumor growth.

Literature DB >> 26290143

A novel nanoparticle containing neuritin peptide with grp170 induces a CTL response to inhibit tumor growth.

Bangqing Yuan¹, Hanchao Shen¹, Tonggang Su¹, Li Lin¹, Ting Chen², Zhao Yang³.

Abstract

Malignant glioma is among the most challenging of all cancers to treat successfully. Despite recent advances in surgery, radiotherapy and chemotherapy, current treatment regimens have only a marginal impact on patient survival. In this study, we constructed a novel nanoparticle containing neuritin peptide with grp170. The nanoparticle could elicit a neuritin-specific cytotoxic T lymphocyte response to lyse glioma cells in vitro. In addition, the nanoparticle could inhibit tumor growth and improve the lifespan of tumor-bearing mice in vivo. Taken together, the results demonstrated that the nanoparticle can inhibit tumor growth and represents a promising therapy for glioma.

Entities: Disease Gene Species

Keywords: CTL; Grp170; Nanoparticle; Neuritin

Mesh：

Substances：

Year: 2015 PMID： 26290143 DOI： 10.1007/s11060-015-1884-0

Source DB: PubMed Journal: J Neurooncol ISSN： 0167-594X Impact factor: 4.130

37 in total

1. Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice.

Authors: Wenqian Huo; Jin Ye; Rongrong Liu; Jin Chen; Qiansheng Li
Journal: Vaccine Date: 2010-07-14 Impact factor: 3.641

2. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Authors: Caterina Giannini; Jann N Sarkaria; Atsushi Saito; Joon H Uhm; Evanthia Galanis; Brett L Carlson; Mark A Schroeder; C David James
Journal: Neuro Oncol Date: 2005-04 Impact factor: 12.300

3. Neuritin expression and its relation with proliferation, apoptosis, and angiogenesis in human astrocytoma.

Authors: Lei Zhang; Yonggeng Zhao; Cheng-guo Wang; Zhou Fei; Yuan Wang; Lexiang Li; Liang Li; Hai-ning Zhen
Journal: Med Oncol Date: 2010-04-20 Impact factor: 3.064

4. The large Hsp70 Grp170 binds to unfolded protein substrates in vivo with a regulation distinct from conventional Hsp70s.

Authors: Julia Behnke; Linda M Hendershot
Journal: J Biol Chem Date: 2013-12-10 Impact factor: 5.157

5. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.

Authors: Xiaofei Yu; Chunqing Guo; Huanfa Yi; Jie Qian; Paul B Fisher; John R Subjeck; Xiang-Yang Wang
Journal: Cancer Res Date: 2013-01-18 Impact factor: 12.701

6. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.

Authors: Thomas J Dilling; Martine Extermann; Jongphil Kim; Lora M Thompson; Binglin Yue; Craig W Stevens; Scott Antonia; Jhanelle Gray; Charles Williams; Eric Haura; Mary Pinder-Schenck; Tawee Tanvetyanon; Sungjune Kim; Alberto Chiappori
Journal: Int J Radiat Oncol Biol Phys Date: 2014-09-09 Impact factor: 7.038

A novel nanoparticle containing neuritin peptide with grp170 induces a CTL response to inhibit tumor growth.

1. Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice.

2. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

3. Neuritin expression and its relation with proliferation, apoptosis, and angiogenesis in human astrocytoma.

4. The large Hsp70 Grp170 binds to unfolded protein substrates in vivo with a regulation distinct from conventional Hsp70s.

5. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.

6. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.

7. Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years.

8. Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.

9. Secretion of stress protein grp170 promotes immune-mediated inhibition of murine prostate tumor.

10. Engineering Grp170-based immune modulators for cancer immunotherapy.

Review 1. Nanoparticles as immunomodulators and translational agents in brain tumors.